Free Newsletter
NICE opens door to Roche, AZ cancer drugs
Free newsletter via e-mail
Tools
The U.K.'s cost-effectiveness watchdog has given the final nod to a trio of cancer drugs--Roche's Xeloda and MabThera, and AstraZeneca's Iressa--which means the NHS must provide funding and resources for them in the next three months. Report
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline
SHARE
WITH: